MedTrace Logo

NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

NCT06966583 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-12

No results posted yet for this study

Summary

This is a phase I, single center (West China Hospital, Sichuan University) study aimed at investigating the safety and efficacy of NMN supplements combined with chemotherapy and radiation therapy for second-line and above treatment of advanced NSCLC.

Conditions

Interventions

DIETARY_SUPPLEMENT

NAD supplement

NAD supplement NMN：NMN12000 GeneHarbor

RADIATION

Radiotherapy

Low Dose Radiotherapy or Stereotactic Ablative Radiotherapy or Conventional Radiotherapy

DRUG

Immunotherapy

PD-1 inhibitor

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Jianxin Xue, doctoral · West China Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2027-06-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06966583 on ClinicalTrials.gov